[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1111935T1 - Διαγονιδιακα ποντικια scce και η χρηση τους ως προτυπα ανθρωπινης ασθενειας - Google Patents

Διαγονιδιακα ποντικια scce και η χρηση τους ως προτυπα ανθρωπινης ασθενειας

Info

Publication number
CY1111935T1
CY1111935T1 CY20111100962T CY111100962T CY1111935T1 CY 1111935 T1 CY1111935 T1 CY 1111935T1 CY 20111100962 T CY20111100962 T CY 20111100962T CY 111100962 T CY111100962 T CY 111100962T CY 1111935 T1 CY1111935 T1 CY 1111935T1
Authority
CY
Cyprus
Prior art keywords
scce
increased
mice
diagnostic
expression
Prior art date
Application number
CY20111100962T
Other languages
English (en)
Inventor
Torbjörn Egelrud
Lennart Hansson
Original Assignee
Torbjörn Egelrud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA2332655A external-priority patent/CA2332655C/en
Application filed by Torbjörn Egelrud filed Critical Torbjörn Egelrud
Publication of CY1111935T1 publication Critical patent/CY1111935T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Environmental Sciences (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)

Abstract

Πρόσφατα παρουσιάστηκε μαρτυρία ότι ανισορροπία στην δραστικότητα πρωτεασών σερίνης μπορεί να προκαλέσει σοβαρή δερματική ασθένεια. Η πρωτεάση σερίνης SCCE εκφράζεται επιλεκτικά σε κερατοποιημένα επιθήλια. Αυξημένη έκφραση του SCCE σε ψωρίαση έχει προηγουμένως ανακοινωθεί. Στο παρόν περιγράφεται επίσης αυξημένη έκφραση SCCE και σε χρόνιες αλλοιώσεις ατοπικής δερματίτιδας. Διαγονιδιακά ποντίκια που εκφράζουν ανθρώπινο SCCE σε υπερβασικά επιδερμικά κερατινοκύτταρα βρέθηκε ότι αναπτύσσουν παθολογικές δερματικές αλλαγές με αυξημένο επιδερμικό πάχος, υπερκεράτωση, δερμική φλεγμονή, και σοβαρό κνησμό. Τα αποτελέσματα ενισχύουν την ιδέα ότι το SCCE μπορεί να εμπλέκεται στην παθογένεση φλεγμονωδών δερματικών ασθενειών, και μπορεί να προσφέρουν νέο θεραπευτικό στόχο.
CY20111100962T 2001-02-09 2011-10-07 Διαγονιδιακα ποντικια scce και η χρηση τους ως προτυπα ανθρωπινης ασθενειας CY1111935T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2332655A CA2332655C (en) 2001-02-09 2001-02-09 Scce modified transgenic mammals and their use as models of human diseases
DKPA200100218 2001-02-09
EP02720389A EP1367886B1 (en) 2001-02-09 2002-02-08 Scce transgenic mice and their use as models of human disease

Publications (1)

Publication Number Publication Date
CY1111935T1 true CY1111935T1 (el) 2015-11-04

Family

ID=25682362

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100962T CY1111935T1 (el) 2001-02-09 2011-10-07 Διαγονιδιακα ποντικια scce και η χρηση τους ως προτυπα ανθρωπινης ασθενειας

Country Status (8)

Country Link
EP (1) EP1367886B1 (el)
JP (1) JP4262479B2 (el)
AT (1) ATE515940T1 (el)
AU (1) AU2002251429B2 (el)
CY (1) CY1111935T1 (el)
DK (1) DK1367886T3 (el)
PT (1) PT1367886E (el)
WO (1) WO2002062135A2 (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1631295T3 (pl) 2003-06-06 2010-09-30 Arexis Ab Zastosowanie skondensowanych związków heterocyklicznych jako inhibitorów SCCE do leczenia chorób skóry
US7247767B2 (en) 2004-01-21 2007-07-24 Boehringer Ingelheim International Gmbh Mouse model for psoriasis and psoriatic arthritis
EP1557085A1 (en) * 2004-01-21 2005-07-27 Boehringer Ingelheim International GmbH Mouse model for human psoriasis
EP1716248A1 (en) * 2004-02-03 2006-11-02 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with kallikrein 7 (klk7)
JP2007530016A (ja) * 2004-02-27 2007-11-01 ザ ジェネラル ホスピタル コーポレーション 発毛のための方法および組成物
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK72593D0 (da) * 1993-06-18 1993-06-18 Symbicom Ab Rekombinant protein
WO1996002254A1 (en) * 1994-07-15 1996-02-01 Michel Cohen SYNERGISTIC PHARMACEUTICAL COMPOSITONS CONTAINING 16'alpha',17'alpha'-ISOPROPYLIDENEDIOXY SUBSTITUTED PREGNANES
WO1998041656A1 (en) * 1997-03-19 1998-09-24 The Board Of Trustees Of The University Of Arkansas Compositions and method for the early diagnosis of ovarian cancer
WO2000058459A1 (de) * 1999-03-29 2000-10-05 Harry Frank Abts Für einen serin protease inhibitor codierende nukleinsäure
EP1356298B1 (en) * 2000-11-30 2011-05-18 Crawford Healthcare Holdings Limited Diagnosis of disease

Also Published As

Publication number Publication date
DK1367886T3 (da) 2011-10-24
JP2004523234A (ja) 2004-08-05
WO2002062135A8 (en) 2004-03-11
ATE515940T1 (de) 2011-07-15
JP4262479B2 (ja) 2009-05-13
WO2002062135A2 (en) 2002-08-15
PT1367886E (pt) 2011-10-03
AU2002251429B2 (en) 2007-01-18
EP1367886A2 (en) 2003-12-10
WO2002062135A3 (en) 2003-09-25
EP1367886B1 (en) 2011-07-13

Similar Documents

Publication Publication Date Title
CY1111935T1 (el) Διαγονιδιακα ποντικια scce και η χρηση τους ως προτυπα ανθρωπινης ασθενειας
Ishida-Yamamoto et al. The biology and regulation of corneodesmosomes
Iba et al. Possible involvement of mast cells in collagen remodeling in the late phase of cutaneous wound healing in mice
Gillespie et al. Varicose veins possess greater quantities of MMP-1 than normal veins and demonstrate regional variation in MMP-1 and MMP-13
Nauroy et al. Kallikreins: Essential epidermal messengers for regulation of the skin microenvironment during homeostasis, repair and disease
Jiang et al. Matrix metalloproteinase inhibitor KB-R7785 attenuates brain damage resulting from permanent focal cerebral ischemia in mice
Zhu et al. Synergistic neutrophil elastase-cytokine interaction degrades collagen in three-dimensional culture
Nygårdas et al. Up-regulation of MMP-8 and MMP-9 activity in the BALB/c mouse spinal cord correlates with the severity of experimental autoimmune encephalomyelitis
ES2121461T3 (es) Utilizacion de un antagonista de cgrp para tratar el eritema cutaneo de origen neurogenico y composicion asi obtenida.
WO2005034940A8 (de) Duale alanyl-aminopeptidase- und dipeptidylpeptidase iv-inhibitoren zur funktionellen beeinflussung unterschiedlicher zellen und zur behandlung immunologischer, entzündlicher, neuronaler und anderer erkrankungen
WO2010118435A3 (en) Par-1 activation by metalloproteinase-1 (mmp-1)
ATE333263T1 (de) Echinacea-extrakt als antireizendes und alterungsschutzmittel für kosmetika
WO2007067735A3 (en) Skin care composition for dermatological disorders
ATE445389T1 (de) Liposomale glucocorticoide
Del Rosso Application of protease technology in dermatology: rationale for incorporation into skin care with initial observations on formulations designed for skin cleansing, maintenance of hydration, and restoration of the epidermal permeability barrier
WO2007099348A3 (en) Cathepsin propeptide and uses thereof
Ke et al. Homocysteine modulates the proteolytic potential of human arterial smooth muscle cells through a reactive oxygen species dependant mechanism
Milstone et al. Treatment of pachyonychia congenita
Dragan et al. Epidermis-intrinsic transcription factor Ovol1 coordinately regulates barrier maintenance and neutrophil accumulation in psoriasis-like inflammation
Fredriksson et al. Red blood cells increase secretion of matrix metalloproteinases from human lung fibroblasts in vitro
Nguyen et al. Limitations of knockout mice and other tools in assessment of the involvement of matrix metalloproteinases in wound healing and the means to overcome them
ATE467423T1 (de) Pharmazeutische zubereitungen als hydrogel, die diaminooxidase enthalten
TW200716192A (en) Use of adamantyl methoxydiphenyl propenoic acid for the treatment of dermatological diseases
Udayashankar et al. Extensive darier’s disease with pityriasis amiantacea, alopecia and congenital facial nerve
Elwell et al. A glossary of terms to assist the recognition and diagnosis of skin conditions associated with lower-limb chronic oedema